https://endpts.com/sanofis-1-5b-deal-with-teva-in-ibd-adds-fuel-to-anti-tl1a-race-against-merck-roivant-and-pfizer/
0
0
Updated: Sanofi's $1.5B pact with Teva in IBD adds fuel to anti-TL1A race against Merck, Roivant and Pfizer - Endpoints News
10/4/23 at 7:49am
Organization
Endpoints News
Authors
Reynald Castañeda Nicole DeFeudis
Details
41 words
Summarize
Business & Industrial Pharmaceuticals & Biotech Teva Pharm Sanofi IBD Merck Roivant Pfizer - Endpoints News
Sanofi wasn't the only party interested in Teva's anti-TL1A antibody, but it emerged as the
Create an account or login to join the discussion